Get informed when a big investor buys or sells
+ Follow-1.51
The Price-to-Book ratio compares a company's market value to its book value. A lower P/B ratio may suggest that the stock is undervalued relative to its assets.
Raphael Pharmaceutical (RAPH) currently reports a P/B ratio of -1.51. That is below the sector sector average of 9.45. Use the charts on this page to explore Raphael Pharmaceutical's P/B ratio history and peer comparisons.
Raphael Pharmaceutical's P/B ratio of -1.51 is lower than the its sector sector average of 9.45. That is roughly 116.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/B ratio is a valuation multiple that relates Raphael Pharmaceutical's market price to a fundamental measure such as earnings, sales, or book value. At -1.51, RAPH can look expensive or cheap only in context — versus its own history, growth rate, and sector peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/B ratio of -1.51, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 9.45. From there, open related valuation or income-statement pages for Raphael Pharmaceutical, and consider following RAPH for alerts when major investors trade the stock.